(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Saturn's moon Titan may not have a buried ocean as long suspected, new study suggests - 2Sydney Sweeney's American Eagle campaign and Kendrick Lamar's Super Bowl performance were among the 10 biggest pop-culture moments of 2025
- 3The 10 Most Persuasive Forerunners in Innovation
- 4Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- 5How Google, Microsoft, Walmart, and other corporate giants are preparing for an aging workforce
- Fundamental Monetary Guidance for Going into Business
- The Best Computer games for Multiplayer Fun
- EU Council president: Ukraine should receive binding guarantees
- Will your baby get a hep B vaccine? What RFK panel's ruling means.
- 19 Strange Motion pictures You Shouldn't Watch With Your Mum
- Instructions to Pick the Right Toothpaste for Your Dental Requirements
- Is 'Veronica Mars' about to be your new binge-watch? It's now streaming on Netflix.
- Wisconsin judge sends Slender Man attacker back to mental health institution after group home escape
- The most effective method to Go with Informed Choices on Vehicle Leases
